CERE - Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Study | Benzinga
On Thursday, Cerevel Therapeutics Holdings Inc. (NASDAQ:CERE) released topline results from its pivotal Phase 3 TEMPO-3 trial for tavapadon in Parkinson’s disease.
The TEMPO-3 trial evaluated the efficacy, safety, and tolerability of tavapadon as an adjunctive therapy to levodopa (LD) in adults.
The trial met its primary endpoint – patients treated with tavapadon adjunctive to LD experienced a clinically meaningful and statistically significant increase of 1.1 hours in total “on” time without troublesome dyskinesia compared to those treated with LD and placebo (1.7 hours vs. 0.6 hours, p <0.0001).